Multiple myeloma is a rare and incurable cancer of plasma cells. To characterize this cancer, we developed an ex vivo drug screening method that combines imaging, deep learning and multiomics and ...

One of the biggest risk is probably aging, myeloma is more common as people grow older. So the median age at which patients get diagnosed with myeloma is about 68/69 years. So it's still predominantly ...

Kyphoplasty has also increasingly been used to treat vertebral osteolyses caused by multiple myeloma (MM). Patients and Methods: In our cohort of 76 patients with MM with a total of 190 vertebral ...

This review summarizes the mechanisms of action and clinical activity of IMiDs in MM. Multiple myeloma (MM) is a malignant plasma cell disorder accounting for approximately 10% of all hematologic ...

Despite being the second most common haematologic cancer globally, treatment options for multiple myeloma remain limited, with a significant need for new therapies. 1 Multiple myeloma originates i ...

Coronary artery disease is the leading cause of death globally. One of the most common tools used to diagnose and monitor ...

Jan. 14, 2025 — A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients.

Dec. 4, 2024 — A new study has shed light on a previously poorly understood aspect of breast cancer recurrence: how cancer cells survive in bone marrow despite targeted ... Vitamin D During ...

Fluorescence imaging is the visualization of fluorescent dyes or proteins as labels for molecular processes or structures. It enables a wide range of experimental observations including the ...

Clayton Irvine, PharmD, MBA, MS, senior manager of oncology care at Mayo Clinic, emphasizes the need for health care providers to balance quality patient care with rising costs by openly ...

All patients involved in the phase 1 trial of a personalized cancer vaccine for high-risk stage III/IV kidney cancer showed a successful anticancer immune response.